C07J 43/00
Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with
Official title: Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
C07J43/00 (Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with) appears on 966 US grants and 901 published applications in this corpus.
Search patents in C07J- Granted patents
- 966
- Published applications
- 901
- Assignees
- 494
- Inventors
- 2,135
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 11 | 0 |
| 1977 | 11 | 0 |
| 1978 | 12 | 0 |
| 1979 | 7 | 0 |
| 1980 | 20 | 0 |
| 1981 | 10 | 0 |
| 1982 | 7 | 0 |
| 1983 | 10 | 0 |
| 1984 | 11 | 0 |
| 1985 | 10 | 0 |
| 1986 | 8 | 0 |
| 1987 | 10 | 0 |
| 1988 | 7 | 0 |
| 1989 | 10 | 0 |
| 1990 | 10 | 0 |
| 1991 | 12 | 0 |
| 1992 | 11 | 0 |
| 1993 | 18 | 0 |
| 1994 | 12 | 0 |
| 1995 | 24 | 0 |
| 1996 | 31 | 0 |
| 1997 | 50 | 0 |
| 1998 | 46 | 0 |
| 1999 | 28 | 0 |
| 2000 | 15 | 0 |
| 2001 | 15 | 2 |
| 2002 | 14 | 16 |
| 2003 | 18 | 23 |
| 2004 | 14 | 19 |
| 2005 | 10 | 16 |
| 2006 | 12 | 20 |
| 2007 | 12 | 22 |
| 2008 | 7 | 11 |
| 2009 | 9 | 19 |
| 2010 | 8 | 19 |
| 2011 | 13 | 25 |
| 2012 | 9 | 23 |
| 2013 | 15 | 24 |
| 2014 | 17 | 43 |
| 2015 | 27 | 33 |
| 2016 | 32 | 58 |
| 2017 | 35 | 49 |
| 2018 | 26 | 41 |
| 2019 | 44 | 51 |
| 2020 | 45 | 56 |
| 2021 | 30 | 59 |
| 2022 | 29 | 50 |
| 2023 | 35 | 69 |
| 2024 | 35 | 59 |
| 2025 | 34 | 52 |
| 2026 | 20 | 42 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Cyclin-dependent kinase inhibitors and methods of use6 Oct 2026US 12,753,203 B2Dana-Farber Cancer Institute, Inc.
- Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof6 Oct 2026US 12,753,204 B2Enanta Pharmaceuticals, Inc.
- Orally active leukemia inhibitory factor (LIF) antagonists for the treatment of cancer29 Sep 2026US 12,747,263 B2Evestra, Inc.
- Solid supports and phosphoramidite building blocks for oligonucleotide conjugates15 Sep 2026US 12,735,387 B2AM Chemicals LLC
- Oxysterol compounds and uses thereof25 Aug 2026US 12,715,893 B2Max Biopharma, Inc.
- Steroid-cationic lipid compound and use thereof8 Oct 2026US 2026/0306406 A1Cansino (Shanghai) Biological Research Co., Ltd.
- Oxysterols and methods of use thereof8 Oct 2026US 2026/0308197 A1Sage Therapeutics, Inc.
- Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders8 Oct 2026US 2026/0308198 A1Sage Therapeutics, Inc.
- Lipids and nanoparticle formulations thereof1 Oct 2026US 2026/0295080 A1Arcturus Therapeutics, Inc.
- Neurosteroids and Prodrugs Thereof24 Sep 2026US 2026/0285897 A1Emory University
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Sugar modified oligonucleotides that detect and modulate gene expression641US 5,670,633 AIsis Pharmaceuticals, Inc. · 1997
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Substituted purines and oligonucleotide cross-linking603US 5,681,941 AIsis Pharmaceuticals, Inc. · 1997